BEAM
NASD Beam Therapeutics, Inc.$24.60 ↑ +0.10 (+0.40%) Trading Up from the previous close of $24.50
- YTD change
- -11.26%
- vs 20-day SMA
- -0.94%
- vs 200-day SMA
- -13.62%
Price ranges
Price & Performance
+0.27 (+1.11%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 82.2% away from all-time highs of $138.52
- BEAM is down 11% since the beginning of the year
- BEAM is down 4% over the past 12 months
- BEAM is down 17% over the past 1 month
- 27% of all BEAM investors are betting against BEAM
BEAM reads not so good: price sits below both the 20- and 200-day averages, the 12-month move is -5.4%.
- Previous minute
- +$0.00
- Last hour
- +$0.08
- Last 5 days
- +1.35%
- vs 8-day SMA
- +0.72%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.